Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
600
Shown on this page
12
Current sort
Recently updated
Campus scope
Children's Hospital of Philadelphia, Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Children's Hospital of Philadelphia, Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 277–288 of 600 matching trials with a site at Children's Hospital of Philadelphia, Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Cord Clamping Among Neonates With Congenital Heart Disease

NCT06153459
Status at this site: Recruiting
View directory record Official record
Conditions
Congenital Heart Disease (CHD)
Interventions
Umbilical Cord Clamping at ~30 seconds, Umbilical Cord Clamping at ~120 seconds, Umbilical Cord Milking
Procedure
Lead sponsor
Carl Backes, MD
Other
Eligibility
37 Weeks to 42 Weeks
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
Site status not listed — check the official record
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting Not applicable Interventional

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

NCT05057702
Status at this site: Recruiting
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma, Ependymoma Malignant, Ependymoma of Brain
Interventions
Specialized Tumor Board Treatment Plan, Combinations
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 39 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting Not applicable Interventional

Creation of a Decision Aid for Coronary Anomalies

NCT07544979
Status at this site: Not yet recruiting
View directory record Official record
Conditions
AAOCA
Interventions
Decision aid
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883
Site status not listed — check the official record
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DYNE-251, Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 16 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756
Site status not listed — check the official record
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting No phase listed Observational

Prospective Research Rare Kidney Stones (ProRKS)

NCT02780297
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hyperoxaluria, Cystinuria, Dent Disease, Lowe Syndrome, Adenine Phosphoribosyltransferase Deficiency
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting Phase 3 Interventional

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

NCT06739122
Status at this site: Recruiting
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

NCT06934967
Status at this site: Recruiting
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

NCT07085338
Status at this site: Recruiting
View directory record Official record
Conditions
Neuroblastoma Recurrent
Interventions
Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 8:17 AM EDT
Active, not recruiting Not applicable Interventional Results available

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

NCT02670525
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy
Interventions
Leukemia Profiling
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 8:17 AM EDT

About this Children's Hospital of Philadelphia institution page

What this page lists
ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.